Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)
AbstractOver the past decade, several drugs have been approved for the treatment of relapsed or refractory multiple myeloma (RRMM). This retrospective study, using the French National Healthcare database (SNDS), describes the treatment patterns and outcomes of patients with RRMM treated in real-world clinical practice in France. Patients were adults, with a diagnosis of multiple myeloma, who initiated second-line (2L) treatment approved for use in France between 2014 and 2018; this included bortezomib, carfilzomib, daratumumab, ixazomib, lenalidomide, or pomalidomide. Data were analyzed overall, by first-line (1L) autologo...
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
AbstractAnti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially reduced with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab. We prospectively analyzed inflammatory cytokines to evaluate the impact of ibrutinib on circulating cytokine levels following obinutuzumab infusion. In iLLUMINATE, ibrutinib or chlorambucil was given approximately 30 –120 min before the first obi...
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis
AbstractChildren with Down syndrome (DS) are at an increased risk of developing transient abnormal myelopoiesis (TAM) and acute leukemia. Aberrant expression of CD56 has been observed on myeloid leukemic blasts in DS patients. In general, CD56 expression in acute myeloid leukemia (AML) is considered a promoter of leukemogenesis. We did a retrospective flow cytometric study to investigate mature myelomonocytic cell CD56 expression patterns in TAM, non-TAM, and leukemia cases with DS. Flow cytometric analysis showed that granulocyte and monocyte aberrant/dysplastic CD56 expression is an inherent characteristic of most DS pat...
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
In this study, a remarkable proportion of transplant-ineligible patients with MM were older, frontline regimens were highly heterogeneous, and patients at higher risk often received less efficacious combinations. These findings suggest that clinicians have limited objective criteria for therapeutic decisions for this patient group. (Source: Annals of Hematology)
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Hepatocellular carcinoma in patients with thalassemia in the post-DAA era: not a disappearing entity
(Source: Annals of Hematology)
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?
(Source: Annals of Hematology)
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

A belated diagnosis of G6PD deficiency in an 81-year-old woman
(Source: Annals of Hematology)
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
A Correction to this paper has been published:https://doi.org/10.1007/s00277-021-04503-1 (Source: Annals of Hematology)
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
A correction to this paper has been published: https://doi.org/10.1007/s00277-021-04545-5 (Source: Annals of Hematology)
Source: Annals of Hematology - June 11, 2021 Category: Hematology Source Type: research

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
AbstractResistance remains the major clinical challenge for the therapy of Philadelphia chromosome –positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation T315I. Here we investigated the therapeutic potential of crizotinib, a TKI approved for targeting ALK and ROS1 in non-small cell lung cancer patients, which inhibited also the ABL1 kinase in cell-free systems, for the treatment of advanced and therapy-resistant Ph+ leukemia. By inhibiting the BCR-ABL1 kinase, crizotinib efficiently suppressed growth ...
Source: Annals of Hematology - June 10, 2021 Category: Hematology Source Type: research

Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib
(Source: Annals of Hematology)
Source: Annals of Hematology - June 10, 2021 Category: Hematology Source Type: research

Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study
AbstractTo explore the differences in the clinical features, treatment responses, and outcomes among children, adolescents, and adults with chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib as first-line therapy. Data from children (0 –8 years for girls and 0–10 years for boys), adolescents (9–19 years for girls and 11–19 years for boys), and adults (age ≥ 20 years) with newly diagnosed CML-CP receiving imatinib as first-line therapy between 2006 and 2019 were retrospectively reviewed. In total, 135 children (c ohort 1), 189 adolescen...
Source: Annals of Hematology - June 5, 2021 Category: Hematology Source Type: research

Successful treatment of hairy cell leukemia variant with obinutuzumab
(Source: Annals of Hematology)
Source: Annals of Hematology - June 4, 2021 Category: Hematology Source Type: research

Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation
(Source: Annals of Hematology)
Source: Annals of Hematology - June 3, 2021 Category: Hematology Source Type: research

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
In this study, we aimed to investigate whether global DNA methylation patterns could predict response to lenalidomide. Genome-wide DNA methylation analysis using Illumina 450k methylation arrays was performed onn=51 patients with MDS del5q who were uniformly treated with lenalidomide in a prospective multicenter trial of the German MDS study group. To study potential direct effects of lenalidomide on DNA methylation, 17 paired samples pre- and post-treatment were analyzed. Our results revealed no relevant effect of lenalidomide on methylation status. Furthermore, methylation patterns prior to therapy could not predict lena...
Source: Annals of Hematology - May 12, 2021 Category: Hematology Source Type: research

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients
AbstractKnowledge on chronic myelomonocytic leukemia (CMML) patients from Argentina and Brazil is limited. Our series of 280 patients depicted an older age at diagnosis (median 72 years old), 26% of aberrant karyotypes, and a prevalence of myelodysplastic (60%) and CMML-0 subtypes (56%). The median overall survival (OS) was 48.2 months for patients in CMML-0 (Ref.), 24.7 months for those in CMML-1 (HR = 2.0,p = 0.001), and 8.8 months for patients in CMML-2 (HR = 4.6,p
Source: Annals of Hematology - May 12, 2021 Category: Hematology Source Type: research

Tissue factor –bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study
AbstractAcute promyelocytic leukemia (APL) cells constitutively express a large amount of tissue factor (TF) antigen, most of which is present in the cytoplasm. Coagulopathy may persist after induction therapy. We evaluated the overall role of circulating microparticles (MPs) in coagulation activation in APL-associated coagulopathy before and during induction therapy. Eleven adult patients with ≥ World Health Organization’s (WHO) grade 2 bleeding events and 11 sex- and age-matched healthy controls were selected. All patients received arsenic trioxide alone as induction therapy. MP-associated TF (MP-TF) activity an...
Source: Annals of Hematology - May 12, 2021 Category: Hematology Source Type: research

Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry
AbstractPost-transplant lymphoproliferative disorders (PTLD) exclusively affecting the central nervous system —primary CNS-PTLD (pCNS-PTLD)—are rare. There is no standard therapy, and previous case series have included heterogeneous treatment approaches. We performed a retrospective, multi-centre analysis of 14 patients with pCNS-PTLD after solid organ transplantation (SOT) treated in the prospective Ge rman PTLD registry with reduction of immunosuppression (RI), whole-brain radiotherapy (WBRT), and concurrent systemic rituximab between 2001 and 2018. Twelve of fourteen patients were kidney transplant recipient...
Source: Annals of Hematology - May 11, 2021 Category: Hematology Source Type: research

A new case of Bic être hemoglobin in an adult male: clinical observations over a period of four years
(Source: Annals of Hematology)
Source: Annals of Hematology - May 11, 2021 Category: Hematology Source Type: research

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
AbstractMultiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conducted an RW comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D) combined with either lenalidomide or pomalidomide plus dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients initiating triplet regimens in line of therapy (LOT) ≥ 2 on/after 1/1/2014 was fo...
Source: Annals of Hematology - May 10, 2021 Category: Hematology Source Type: research

What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?
AbstractPatients undergoing allogeneic stem cell transplantation (allo-SCT) are given a real chance of cure, but at the same time are confronted with a considerable risk of mortality and of severe long-term impediments. This narrative, non-systematic literature review aims to describe the supportive and palliative care needs of allo-SCT recipients, including long-term survivors or those relapsing or dying after transplantation. It also evaluates the feasibility and effectivity of integrating palliative care early in transplant procedures. In this appraisal of available literature, the main findings relate to symptoms like ...
Source: Annals of Hematology - May 6, 2021 Category: Hematology Source Type: research

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
(Source: Annals of Hematology)
Source: Annals of Hematology - May 6, 2021 Category: Hematology Source Type: research

Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
AbstractDespite the widespread use of rabbit anti-thymocyte globulin (ATG) to prevent acute and chronic graft-versus-host disease (aGVHD, cGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), convincing evidence about an optimal dose is lacking. We retrospectively evaluated the clinical impact of two different ATG doses (5 vs 6 –7.5 mg/kg) in 395 adult patients undergoing HSCT from matched unrelated donors (MUD) at 3 Italian centers. Cumulative incidence of aGVHD and moderate-severe cGVHD did not differ in the 2 groups. We observed a trend toward prolonged overall survival (OS) and disease-free survi...
Source: Annals of Hematology - May 4, 2021 Category: Hematology Source Type: research

Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice —data from a Belgian registry
AbstractData on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016 –2019) in Belgium (NCT03678454). Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were treated with ponatinib per current label. Fifty patients (33 CML and 17 Ph+ ALL) were enrolled. Fifty-five percent of CML and 29% of Ph+ A LL patients had received ≥3 prior tyrosine kinase inhibitors (TKIs). Reasons for starting ponatinib were intolerance (40%), relapse or refractoriness (2...
Source: Annals of Hematology - May 4, 2021 Category: Hematology Source Type: research

Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis
AbstractBloodstream infections (BSI) are a frequent complication in patients with hematological and oncological diseases. However, the impact of different bacterial species causing BSI and of multiple BSI remains incompletely understood. We performed a retrospective study profiling 637 bacterial BSI episodes in hematological and oncological patients. Based on the 30-day (30d) overall survival (OS), we analyzed different types of multiple BSI and grouped BSI-associated bacteria into clusters followed by further assessment of clinical and infection-related characteristics. We discovered that polymicrobial BSI (different orga...
Source: Annals of Hematology - May 3, 2021 Category: Hematology Source Type: research

Oral therapy adherence and satisfaction in patients with multiple myeloma
AbstractThe transition to oral therapies in patients with multiple myeloma (MM) offers potential benefits to patients; however, they must self-manage their medication and adherence plays an important role in patient care. It has been shown that patient satisfaction with their medication has a strong positive correlation with adherence in chronic diseases. The aim of this study was to estimate adherence rate of oral antimyeloma therapies and to identify risk factors for medication non-adherence. This observational, prospective, and multicentre survey based on a self-report questionnaire enrolled MM patients with at least 3 ...
Source: Annals of Hematology - May 3, 2021 Category: Hematology Source Type: research

Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center
This study aimed to explore the prognostic significance of different KIT mutation subtypes and minimal residual disease (MRD) in CBF-AML. We retrospectively evaluated continuous patients diagnosed with CBF-AML in our center between January 2014 and April 2019. Of the 215 patients, 147 (68.4%) and 68 (31.6%) patients were RUNX1-RUNX1T1- and CBFB-MYH11 positive, respectively. KIT mutations were found in 71 (33.0%) patients; of them, 38 (53.5%) had D816/D820 mutations. After excluding 10 patients who died or were lost to follow-up within a half year, 42.0% (n = 86) of the remaining 205 patients received allogeneic hematopoiet...
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”
AbstractCarfilzomib, a next-generation proteasome inhibitor, improves outcomes in patients with multiple myeloma (MM); however, a proportion of those treated develop renal failure due to adverse event, comorbidity, or myeloma progression. The rate of renal failure and associated risk factors remains unknown in real-world populations. Adults with relapsed/refractory MM who received carfilzomib between the years 2013 and 2016 were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases. Renal failure was defined using the corresponding International Classification of Diseases, Ninth Rev...
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Clinical Impact of Extranodal Metabolic Tumor Volume in 240 Diffuse Large B cell Lymphoma Patients with Extranodal Involvement
AbstractThe present study is to investigate whether extranodal (EN) metabolic tumor volume (MTV) would have a specific clinical meaning for survival in EN diffuse large B cell lymphoma (DLBCL) patients. Two hundred forty DLBCL patients with EN involvement received 18F-fluorodeoxygenase (FDG) positron emission tomography/computed tomography (PET/CT) were enrolled. Survival analysis revealed that low EN MTV (PFS [progression-free survival], HR = 0.278, 95% CI = 0.127–0.807,p = 0.001; OS [overall survival], HR = 0.320, 95% CI = 0.145–0.703,p = 0.003), low total MTV (PFS, HR = 0.194, 95% CI = 0.085–0.445,p
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
AbstractThis analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib + LDAC (de novo,n = 38; secondary acute myeloid leukemia,n = 40) or LDAC alone (de novo,n = 18; secondary acute myeloid leukemia,n = 20). At the time of analysis, 90% of patients had died, with the longest follow-up since randomization 36 months. The combination of glasdegib and LDAC conferred superior overall survival (OS...
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival
AbstractThis is a retrospective study comparing the effectiveness of umbilical cord blood transplantation (UCBT) and chemotherapy for patients in the first complete remission period for acute myeloid leukemia with KMT2A-MLLT3 rearrangements. A total of 22 patients were included, all of whom achieved first complete remission (CR1) through 1 –2 rounds of induction chemotherapy, excluding patients with an early relapse. Twelve patients were treated with UCBT, and 10 patients were treated with chemotherapy after 2 to 4 courses of consolidation therapy. The 3-year overall survival (OS) of the UCBT group was 71.3% (95% CI,...
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia
(Source: Annals of Hematology)
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera
(Source: Annals of Hematology)
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

dsDNA from extracellular vesicles (EVs) in adult AML
(Source: Annals of Hematology)
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor
(Source: Annals of Hematology)
Source: Annals of Hematology - April 13, 2021 Category: Hematology Source Type: research

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome —excess blasts detected by next-generation sequencing technique
This study aimed to determine the incidence and clinical impact of molecular genetic aberrations in Thai patients with AML and MDS-EB, detected by the next-generation sequencing (NGS) technique. This prospective, observational study was conducted between 2018 and 2020 on newly diagnosed Thai AML or MDS-EB patients aged above 15 years. NGS was performed using a custom amplicon-based targeted enrichment assay for 42 genes recurrently mutated in myeloid neoplasms. The molecular results were correlated with baseline patient and disease characteristics as well as outcomes.  Forty-nine patients were enrolled in this study. ...
Source: Annals of Hematology - April 10, 2021 Category: Hematology Source Type: research

Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone
In conclusion, our results emphasized the role ofcereblon mRNA expression as a unique biomarker for predicting the clinical response and outcome of lenalidomide-based therapy in newly diagnosed POEMS syndrome patients. (Source: Annals of Hematology)
Source: Annals of Hematology - April 10, 2021 Category: Hematology Source Type: research

Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study
AbstractOptions for anemic lower-risk myelodysplastic syndromes (MDS) without del(5q) after failure of erythropoiesis-stimulating agents (ESAs) are very limited. The effectiveness of second-line treatments is uncertain. We retrospectively reviewed the clinical effectiveness and overall survival (OS) of lower-risk MDS without del(5q) patients exclusively treated with stanozolol (STZ) after failure of epoetin alfa. The response was defined according to the 2006 International Working Group (IWG) criteria. Fifty-six patients were included. The median follow-up time was 55 months (range: 5 –156 months). Twenty-seven patie...
Source: Annals of Hematology - April 10, 2021 Category: Hematology Source Type: research

A Filipino infant with severe neutropenia owing to SRP54 mutations was successfully treated with ethnically mismatched cord blood transplantation from a Japanese cord blood bank
(Source: Annals of Hematology)
Source: Annals of Hematology - April 10, 2021 Category: Hematology Source Type: research

Education of early palliative care specialists among hematologists and oncologists to address patients ’ rather than physicians’ rights
(Source: Annals of Hematology)
Source: Annals of Hematology - April 10, 2021 Category: Hematology Source Type: research

δ-Hemoglobinopathies in Thailand: screening, molecular basis, genotype-phenotype interaction, and implication for prevention and control of thalassemia
We report an extensive molecular characterization of δ-hemoglobinopathies in Thailand. Study was done on 32,108 subjects, encountered at the thalassemia screening. Six different approaches based on the reduced Hb A2 or appearance of Hb A2-derivative were established for selective recruitment of subjects. Among 32,108 subjects, a total of 296 subjects were suspected of having δ-globin gene defects. Of these 296 subjects, Hb and DNA analyses identified δ-hemoglobinopathies with 10 different mutations in 34 (0.11%) of them. These included a novel mutation, [δCD30(AGG>GGG) (n = 1)], 5 previously unde...
Source: Annals of Hematology - April 8, 2021 Category: Hematology Source Type: research

Allogeneic stem cell transplantation for mantle cell lymphoma —update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)
AbstractMantle cell lymphoma (MCL) is a non-Hodgkin ’s lymphoma with an often aggressive course, incurable by chemotherapy. Consolidation with high-dose therapy and autologous stem cell transplantation (autoSCT) has a low transplant-related mortality but does not lead to a survival plateau. Allogeneic stem cell transplantation (alloSCT) is associat ed with a higher early mortality, but can cure MCL. To investigate alloSCT for therapy of MCL, we conducted two prospective trials for de novo MCL (OSHO#74) and for relapsed or refractory MCL (OSHO#60). Fifteen and 24 patients were recruited, respectively. Induction was ma...
Source: Annals of Hematology - April 8, 2021 Category: Hematology Source Type: research

CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia
AbstractChronic neutrophilic leukemia (CNL) is a rare but serious myeloid malignancy. In a review of reported cases for WHO-defined CNL, CSF3R mutation is found in about 90% cases and confirmed as the molecular basis of CNL. Concurrent mutations are observed in CSF3R-mutated CNL patients, including ASXL1, SETBP1, SRSF2, JAK2, CALR, TET2, NRAS, U2AF1, and CBL. Both ASXL1 and SETBP1 mutations in CNL have been associated with a poor prognosis, whereas, SRSF2 mutation was undetermined. Our patient was a 77-year-old man and had no significant past medical history and symptoms with leukocytosis. Bone marrow (BM) aspirate and bio...
Source: Annals of Hematology - April 6, 2021 Category: Hematology Source Type: research

Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients
AbstractHydroxyurea (HU) and thalidomide have been reported to improve clinical and hematological parameters in transfusion-dependent beta thalassemia (TDT). Therefore, we retrospectively analyzed the combination of HU and thalidomide in 140 transplant ineligible TDT, ≥ 10 years old, visiting our thalassemia clinic between October 2014 and November 2019. Responses were defined as maintenance of hemoglobin ≥9gm/dl without transfusion as complete response (CR) and with at least 50% reduction in transfusion burden as partial response (PR). Patients with less tha n 50% transfusion burden reduction for consecutive 6 month...
Source: Annals of Hematology - April 3, 2021 Category: Hematology Source Type: research

Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review
AbstractThe incidence of acute myeloid leukemia increases with age, and more than half of AML patients are over 60  years old. Treating elderly AML patients presents several challenges and uncertainties, linked partly to disease characteristics and partly to the difficulty of establishing which patients could benefit from the best treatment. Although some elderly fit patients can receive intensive therapy, many of them are not treated and not enrolled in clinical trials. Yet supportive care is associated with significantly lower survival rates compared to intensive therapy or lower intensive therapy. A poorer prognosi...
Source: Annals of Hematology - April 2, 2021 Category: Hematology Source Type: research

Neutrophil gelatinase –associated lipocalin as a biomarker of nephropathy in sickle cell disease
This study evaluates the role of neutrophil gelatinase –associated lipocalin (NGAL) as a biomarker of SCN in steady state and vaso-occlusive crisis (VOC). In this case-control study, 74 sickle cell disease (SCD) patients (37 in steady state and 37 in VOC) and 53 control subjects had hematological and biochemical measurements including plasma and urine NGAL. Univariate and logistic regression analyses were used to find the associations between variables. The receiver operating characteristic (ROC) curve was used to determine the diagnostic performance characteristics of plasma and urine NGAL for detection of VOC. Plas...
Source: Annals of Hematology - April 2, 2021 Category: Hematology Source Type: research

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
AbstractAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially curative for acute myeloid leukemia (AML). The inherent graft-versus-leukemia activity (GvL) may be optimized by donor lymphocyte infusions (DLI). Here we present our single-center experience of DLI use patterns and effectiveness, based on 342 consecutive adult patients receiving a first allo-HSCT for AML between 2009 and 2017. The median age at transplantation was 57 years (range 19 –79), and the pre-transplant status was active disease in 58% and complete remission (CR) in 42% of cases. In a combined landmark analysis, patients in...
Source: Annals of Hematology - April 1, 2021 Category: Hematology Source Type: research

Hepcidin and other indicators of iron status, by alpha-1 acid glycoprotein levels, in a cohort of Mexican infants
AbstractThe purpose of this study was to describe the changes in iron status indicators at 6 and 12  months of age, controlling by inflammation by measuring alpha-1 acid glycoprotein (AGP). This longitudinal study included 48 healthy-term singleton infants with birth weight ≥ 2500 g, born in hospitals of the Mexican Institute for Social Security. Complete blood count, ferritin, soluble trans ferrin receptor (sTfR), hepcidin, and AGP were measured in blood at 6 and 12 months of age. sTfR/ferritin ratio and total body iron (TBI) stores were calculated. Hemoglobin and sTfR/ferritin ratio increased wit...
Source: Annals of Hematology - March 15, 2021 Category: Hematology Source Type: research

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort
AbstractThe BCL2 inhibitor venetoclax is transforming the management of patients with chronic lymphocytic leukemia (CLL), given its high efficacy in relapsed/refractory CLL as observed in both early-phase and randomized clinical trials. The present study aimed to determine whether venetoclax is effective and well tolerated in patients with CLL or Richter ’s syndrome (RS) in a real-world setting and to highlight factors impacting survival. Data from a venetoclax French compassionate use program were collected for 67 patients (60 with CLL and 7 with RS). Most patients presented adverse genetic features, such asTP53 dis...
Source: Annals of Hematology - March 15, 2021 Category: Hematology Source Type: research

Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma —data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)
AbstractIn elderly patients (pts) with aggressive B cell lymphoma (aNHL), curative treatment often cannot be administered because of comorbidities and tolerability. We analyzed the influence of age in pts> 60 years receiving the R-CHOP-14 regimen within different prospective DSHNHL trials. Of the RICOVER-60 trial and CHOP-R-ESC trials, 1171 aNHL pts were included in this retrospective analysis of age-dependent event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). All patients received prophylactic G-CSF, and anti-infective prophylaxis with amphotericin B mouth wash and oral fluorchinolon...
Source: Annals of Hematology - March 15, 2021 Category: Hematology Source Type: research